Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $109.90.
Several brokerages have commented on PRAX. Wedbush upped their target price on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the company an “underperform” rating in a research note on Monday, May 5th. Robert W. Baird decreased their price target on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Oppenheimer set a $97.00 price objective on shares of Praxis Precision Medicines and gave the company an “outperform” rating in a research report on Monday, June 2nd. Truist Financial dropped their price objective on Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $105.00 target price on shares of Praxis Precision Medicines in a research note on Thursday, May 1st.
View Our Latest Research Report on PRAX
Institutional Investors Weigh In On Praxis Precision Medicines
Praxis Precision Medicines Trading Down 2.4%
NASDAQ:PRAX opened at $43.00 on Friday. Praxis Precision Medicines has a 1-year low of $26.70 and a 1-year high of $91.83. The firm has a market capitalization of $875.91 million, a price-to-earnings ratio of -4.01 and a beta of 2.60. The business’s 50-day moving average price is $39.77 and its two-hundred day moving average price is $52.92.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported ($3.29) EPS for the quarter, missing analysts’ consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 50.42%. Sell-side analysts predict that Praxis Precision Medicines will post -10.22 earnings per share for the current year.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Featured Stories
- Five stocks we like better than Praxis Precision Medicines
- Top Stocks Investing in 5G Technology
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- How to Invest in Small Cap Stocks
- 3 Stocks Hitting All-Time Highs With More Room to Run
- 3 REITs to Buy and Hold for the Long Term
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.